MetaCap

Immunic (IMUX) vs Spruce Biosciences (SPRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immunic (IMUX) has outperformed Spruce Biosciences (SPRB) over the past year, gaining 1.9% versus a loss of 63.8%. Over five years, IMUX leads with a -91.9% price change compared with -99.8% for SPRB. Immunic is the larger company by market cap ($111.0 million vs $109.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMUX+1.90%SPRB-63.81%
+157%+41%-74%
Nov 21, 20251 yearNov 20, 2026
IMUX-92.54%SPRB-99.77%
+97%-6%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMUX versus SPRB key metrics
MetricIMUXSPRB
Share price$6.99$38.00
Market cap$111.01M$109.21M
1-day change-5.41%-6.15%
YTD return+30.90%-56.38%
1-year return+1.90%-63.81%
5-year return-91.88%-99.75%
Forward P/E—11.79
EPS (TTM)$-3.53$-33.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-97.17M$-38.97M
52-week high$17.43$111.00
52-week low$5.06$38.00
Distance from 52-week high-59.90%-65.77%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+508.73%+288.00%
Average volume343.44K89.33K
Shares outstanding15.88M2.87M
Employees10025
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMUX has outperformed SPRB by 65.7 percentage points over the past year.

About Immunic

IMUX stock →

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Spruce Biosciences

SPRB stock →

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

IMUX vs SPRB FAQ

Which is bigger, Immunic or Spruce Biosciences?

Immunic (IMUX) is larger, with a market capitalization of $111.01M compared with $109.21M for Spruce Biosciences (SPRB).

Which stock has performed better over the past year, IMUX or SPRB?

IMUX returned +1.90% over the past 12 months, compared with -63.81% for SPRB (price return, excluding dividends). Past performance does not predict future results.

Are Immunic and Spruce Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons